IDH2 and acute myeloid leukemia: The identification of targetable AML-specific surface markers, driver oncogenes and cellular pathways finally led to the development of new effective treatments; see Figure 1 [132,133] In the last few years, six new drugs have been approved by the U.S. Food and Drug Administration (FDA) for the treatment of newly diagnosed or relapsed or refractory (R/R) AML in UNFIT patients: the FLT3 inhibitor gilteritinib, the IDH inhibitors ivosidenib and enasidenib, the anti-CD33 monoclonal antibody gemtuzumab ozogamicin, the hedgehog pathway inhibitor glasdegib and the BCL-2 inhibitor venetoclax [10].